Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHG Pharmaceutical JSCSTC:DHG -0.11%77 EV-to-EBIT is 8.87 as of Aug. 01, 2026, which is 30% below its 10-year median of 12.63. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,458.71 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 692 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 76.01% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
DHG Pharmaceutical JSC's Enterprise Value for the quarter that ended in Jun. 2026 was ₫10,486,180 Mil.
DHG Pharmaceutical JSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫1,173,343 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's EV-to-EBIT falls into.
DHG Pharmaceutical JSC's current Enterprise Value is ₫10,407,739 Mil.
DHG Pharmaceutical JSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫1,173,343 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHG Pharmaceutical JSC (STC:DHG) has a EV-to-EBIT of 8.87 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on DHG Pharmaceutical JSC and its competitors. This is 30% below median its historical median of 12.63. Over the past decade, DHG Pharmaceutical JSC's EV-to-EBIT has ranged from 7.96 to 21.62. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #166 out of 692 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is DHG Pharmaceutical JSC's EV-to-EBIT too high?
DHG Pharmaceutical JSC's current EV-to-EBIT of 8.87 is 30% below median its 10-year median of 12.63. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 21.62. The Drug Manufacturers industry median EV-to-EBIT is 15.77. DHG Pharmaceutical JSC's value of 8.87 is 43.8% below this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #166 out of 692 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #166 out of 692 companies for EV-to-EBIT. This places DHG Pharmaceutical JSC in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.77. DHG Pharmaceutical JSC's value of 8.87 is 43.8% below this benchmark. Historically, DHG Pharmaceutical JSC's own EV-to-EBIT has ranged from 7.96 to 21.62 over the past decade. While the company's 10-year median is 12.63 vs. the industry median of 15.77, DHG Pharmaceutical JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current EV-to-EBIT of 8.87 is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current EV-to-EBIT is 8.87, which is 30% below median its own 10-year median of 12.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,458.71, compared to a current price of ₫92,600.00 — trading 18.4% below its estimated fair value. The current EV-to-EBIT is 8.87, which is 30% below median its 10-year median of 12.63 and 43.8% below the Drug Manufacturers industry median of 15.77. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current EV-to-EBIT is 8.87 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫92,600.00 is trading 18.4% below its estimated GF Value™ of ₫113,458.71.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
EV-to-EBIT: 8.87 (30% below median its 10-year median of 12.63)
GF Value™: ₫113,458.71 vs. price of ₫92,600.00 (18.4% below fair value)
Industry Position: 43.8% below the Drug Manufacturers median (#166 of 692)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
